HEADER TRANSFERASE 30-NOV-11 4AA5 TITLE P38ALPHA MAP KINASE BOUND TO CMPD 33 COMPND MOL_ID: 1; COMPND 2 MOLECULE: MITOGEN-ACTIVATED PROTEIN KINASE 14; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: MAP KINASE 14, MAPK 14, CYTOKINE SUPPRESSIVE ANTI- COMPND 5 INFLAMMATORY DRUG-BINDING PROTEIN, CSAID-BINDING PROTEIN, CSBP, MAP COMPND 6 KINASE MXI2, MAX-INTERACTING PROTEIN 2, MITOGEN-ACTIVATED PROTEIN COMPND 7 KINASE P38 ALPHA, MAP KINASE P38 ALPHA, STRESS-ACTIVATED PROTEIN COMPND 8 KINASE 2A, SAPK2A, P38ALPHA MAP KINASE; COMPND 9 EC: 2.7.11.24, 2.7.1.37; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PT7 3.3 KEYWDS SERINE/THREONINE KINASE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR S.GERHARDT,D.HARGREAVES REVDAT 5 06-FEB-19 4AA5 1 REMARK REVDAT 4 30-JAN-19 4AA5 1 REMARK REVDAT 3 28-JUN-17 4AA5 1 REMARK REVDAT 2 06-JUN-12 4AA5 1 JRNL REVDAT 1 16-MAY-12 4AA5 0 JRNL AUTH D.S.BROWN,J.G.CUMMING,P.BETHEL,J.FINLAYSON,S.GERHARDT, JRNL AUTH 2 I.NASH,R.PAUPTIT,K.G.PIKE,A.REID,W.SNELSON,S.SWALLOW, JRNL AUTH 3 C.THOMPSON JRNL TITL THE DISCOVERY OF JRNL TITL 2 N-CYCLOPROPYL-4-METHYL-3-[6--(4-METHYLPIPERAZIN-1-YL-4-OXOQU JRNL TITL 3 INAZOLIN-3(4H)-YL]BENZAMIDE (AZD6703), A CLINICAL P38ALPHA JRNL TITL 4 MAP KINASE INHIBITOR FOR THE TREATMENT OF INFLAMMATORY JRNL TITL 5 DISEASES JRNL REF BIOORG.MED.CHEM.LETT. V. 22 3879 2012 JRNL REFN ISSN 0960-894X JRNL PMID 22608965 JRNL DOI 10.1016/J.BMCL.2012.04.116 REMARK 2 REMARK 2 RESOLUTION. 2.38 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.6.0113 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.38 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 19.32 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 94.1 REMARK 3 NUMBER OF REFLECTIONS : 13693 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.218 REMARK 3 R VALUE (WORKING SET) : 0.216 REMARK 3 FREE R VALUE : 0.260 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 724 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.38 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.44 REMARK 3 REFLECTION IN BIN (WORKING SET) : 796 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 82.25 REMARK 3 BIN R VALUE (WORKING SET) : 0.2760 REMARK 3 BIN FREE R VALUE SET COUNT : 43 REMARK 3 BIN FREE R VALUE : 0.4600 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2751 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 31 REMARK 3 SOLVENT ATOMS : 21 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 34.39 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.83000 REMARK 3 B22 (A**2) : -0.87000 REMARK 3 B33 (A**2) : 2.69000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.568 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.290 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.222 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 20.054 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.929 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.905 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2850 ; 0.014 ; 0.020 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3873 ; 1.401 ; 1.976 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 338 ; 6.303 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 132 ;39.529 ;23.712 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 484 ;17.669 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 19 ;22.173 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 432 ; 0.086 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2153 ; 0.006 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 5 A 352 REMARK 3 ORIGIN FOR THE GROUP (A): 6.2115 3.5812 15.0774 REMARK 3 T TENSOR REMARK 3 T11: 0.0993 T22: 0.0096 REMARK 3 T33: 0.0359 T12: 0.0128 REMARK 3 T13: 0.0414 T23: 0.0121 REMARK 3 L TENSOR REMARK 3 L11: 3.6509 L22: 1.0381 REMARK 3 L33: 1.3661 L12: -0.0275 REMARK 3 L13: 0.2237 L23: -0.2119 REMARK 3 S TENSOR REMARK 3 S11: 0.0020 S12: -0.0843 S13: 0.1119 REMARK 3 S21: -0.0336 S22: -0.0152 S23: -0.0506 REMARK 3 S31: -0.0315 S32: 0.0126 S33: 0.0132 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. DISORDERED REGIONS WERE NOT MODELED IN THE FINAL REMARK 3 STRUCTURE. REMARK 4 REMARK 4 4AA5 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 30-NOV-11. REMARK 100 THE DEPOSITION ID IS D_1290050533. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 07-JAN-03 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : ENRAF-NONIUS FR591 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15291 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.380 REMARK 200 RESOLUTION RANGE LOW (A) : 19.320 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.5 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.05000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 15.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.38 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.51 REMARK 200 COMPLETENESS FOR SHELL (%) : 90.3 REMARK 200 DATA REDUNDANCY IN SHELL : 3.60 REMARK 200 R MERGE FOR SHELL (I) : 0.28000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 5.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.10 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.24 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 6-10% PEG-MME 5000, PH 6.5, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 32.24000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 38.19950 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 37.32700 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 38.19950 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 32.24000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 37.32700 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 HIS A -4 REMARK 465 HIS A -3 REMARK 465 HIS A -2 REMARK 465 HIS A -1 REMARK 465 HIS A 0 REMARK 465 HIS A 1 REMARK 465 SER A 2 REMARK 465 GLN A 3 REMARK 465 GLU A 4 REMARK 465 LYS A 118 REMARK 465 CYS A 119 REMARK 465 GLN A 120 REMARK 465 LYS A 121 REMARK 465 ASP A 176 REMARK 465 ASP A 177 REMARK 465 GLU A 178 REMARK 465 LEU A 353 REMARK 465 ASP A 354 REMARK 465 GLN A 355 REMARK 465 GLU A 356 REMARK 465 GLU A 357 REMARK 465 MET A 358 REMARK 465 GLU A 359 REMARK 465 SER A 360 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 HIS A 107 CG HIS A 107 CD2 0.055 REMARK 500 HIS A 126 CG HIS A 126 CD2 0.060 REMARK 500 HIS A 174 CG HIS A 174 CD2 0.065 REMARK 500 TRP A 197 CE2 TRP A 197 CD2 0.072 REMARK 500 HIS A 199 CG HIS A 199 CD2 0.066 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 67 NE - CZ - NH1 ANGL. DEV. = 3.0 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLN A 11 122.47 -170.46 REMARK 500 LYS A 15 -43.36 104.28 REMARK 500 ARG A 149 -20.09 77.98 REMARK 500 ASP A 150 45.33 -140.48 REMARK 500 ASN A 196 26.30 34.69 REMARK 500 HIS A 199 150.40 -41.54 REMARK 500 PHE A 274 67.02 -103.79 REMARK 500 LEU A 289 50.23 -96.45 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NQB A 1353 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2BAJ RELATED DB: PDB REMARK 900 P38ALPHA BOUND TO PYRAZOLOUREA REMARK 900 RELATED ID: 1WFC RELATED DB: PDB REMARK 900 STRUCTURE OF APO, UNPHOSPHORYLATED, P38 MITOGEN ACTIVATEDPROTEIN REMARK 900 KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUEOF THE YEAST REMARK 900 HOG1 PROTEIN REMARK 900 RELATED ID: 3ZSI RELATED DB: PDB REMARK 900 X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745 REMARK 900 RELATED ID: 1W7H RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1WBO RELATED DB: PDB REMARK 900 FRAGMENT BASED P38 INHIBITORS REMARK 900 RELATED ID: 1KV2 RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796 REMARK 900 RELATED ID: 1YQJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A REMARK 900 SELECTIVEPYRIDAZINE INHIBITOR REMARK 900 RELATED ID: 1BMK RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655 REMARK 900 RELATED ID: 1BL7 RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025 REMARK 900 RELATED ID: 1ZYJ RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A REMARK 900 RELATED ID: 1A9U RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580 REMARK 900 RELATED ID: 1WBT RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING REMARK 900 FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 2I0H RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA IN COMPLEX WITH ANARYLPYRIDAZINONE REMARK 900 RELATED ID: 3ZS5 RELATED DB: PDB REMARK 900 STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2YIW RELATED DB: PDB REMARK 900 TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE REMARK 900 RELATED ID: 2BAQ RELATED DB: PDB REMARK 900 P38ALPHA BOUND TO RO3201195 REMARK 900 RELATED ID: 1WBV RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING REMARK 900 FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 1ZZ2 RELATED DB: PDB REMARK 900 TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING ACOMMON REMARK 900 DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDINGMODES REMARK 900 RELATED ID: 1DI9 RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE INCOMPLEX REMARK 900 WITH 4-[3-METHYLSULFANYLANILINO]-6,7- DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1W83 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1BL6 RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995 REMARK 900 RELATED ID: 1M7Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH REMARK 900 ADIHYDROQUINAZOLINONE INHIBITOR REMARK 900 RELATED ID: 3ZSH RELATED DB: PDB REMARK 900 X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469 REMARK 900 RELATED ID: 1IAN RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE INHIBITOR COMPLEX REMARK 900 RELATED ID: 1OZ1 RELATED DB: PDB REMARK 900 P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4- AZAINDOLEINHIBITOR REMARK 900 RELATED ID: 1WBN RELATED DB: PDB REMARK 900 FRAGMENT BASED P38 INHIBITORS REMARK 900 RELATED ID: 2BAK RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO MPAQ REMARK 900 RELATED ID: 3ZYA RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO- PHENYLAMINO- REMARK 900 DIBENZOSUBERONE REMARK 900 RELATED ID: 3ZSG RELATED DB: PDB REMARK 900 X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715 REMARK 900 RELATED ID: 2BAL RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE REMARK 900 RELATED ID: 1WBS RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING REMARK 900 FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 1OUK RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH APYRIDINYLIMIDAZOLE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OUY RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2Y8O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A MAPK DOCKING REMARK 900 PEPTIDE REMARK 900 RELATED ID: 1R39 RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA REMARK 900 RELATED ID: 2YIS RELATED DB: PDB REMARK 900 TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE. REMARK 900 RELATED ID: 1KV1 RELATED DB: PDB REMARK 900 P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1 REMARK 900 RELATED ID: 1WBW RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING REMARK 900 FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 1W82 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2YIX RELATED DB: PDB REMARK 900 TRIAZOLOPYRIDINE INHIBITORS OF P38 REMARK 900 RELATED ID: 1R3C RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA C162S MUTANT REMARK 900 RELATED ID: 1OVE RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH ADIHYDROQUINOLINONE REMARK 900 RELATED ID: 1W84 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1ZZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE REMARK 900 RELATED ID: 4AA0 RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO CMPD 2 REMARK 900 RELATED ID: 4AA4 RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO CMPD 22 REMARK 900 RELATED ID: 4AAC RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO CMPD 29 REMARK 999 REMARK 999 SEQUENCE REMARK 999 N-TERMINAL HEXA-HIS EXPRESSION TAG DBREF 4AA5 A 2 360 UNP Q16539 MK14_HUMAN 2 360 SEQADV 4AA5 HIS A -4 UNP Q16539 EXPRESSION TAG SEQADV 4AA5 HIS A -3 UNP Q16539 EXPRESSION TAG SEQADV 4AA5 HIS A -2 UNP Q16539 EXPRESSION TAG SEQADV 4AA5 HIS A -1 UNP Q16539 EXPRESSION TAG SEQADV 4AA5 HIS A 0 UNP Q16539 EXPRESSION TAG SEQADV 4AA5 HIS A 1 UNP Q16539 EXPRESSION TAG SEQRES 1 A 365 HIS HIS HIS HIS HIS HIS SER GLN GLU ARG PRO THR PHE SEQRES 2 A 365 TYR ARG GLN GLU LEU ASN LYS THR ILE TRP GLU VAL PRO SEQRES 3 A 365 GLU ARG TYR GLN ASN LEU SER PRO VAL GLY SER GLY ALA SEQRES 4 A 365 TYR GLY SER VAL CYS ALA ALA PHE ASP THR LYS THR GLY SEQRES 5 A 365 LEU ARG VAL ALA VAL LYS LYS LEU SER ARG PRO PHE GLN SEQRES 6 A 365 SER ILE ILE HIS ALA LYS ARG THR TYR ARG GLU LEU ARG SEQRES 7 A 365 LEU LEU LYS HIS MET LYS HIS GLU ASN VAL ILE GLY LEU SEQRES 8 A 365 LEU ASP VAL PHE THR PRO ALA ARG SER LEU GLU GLU PHE SEQRES 9 A 365 ASN ASP VAL TYR LEU VAL THR HIS LEU MET GLY ALA ASP SEQRES 10 A 365 LEU ASN ASN ILE VAL LYS CYS GLN LYS LEU THR ASP ASP SEQRES 11 A 365 HIS VAL GLN PHE LEU ILE TYR GLN ILE LEU ARG GLY LEU SEQRES 12 A 365 LYS TYR ILE HIS SER ALA ASP ILE ILE HIS ARG ASP LEU SEQRES 13 A 365 LYS PRO SER ASN LEU ALA VAL ASN GLU ASP CSS GLU LEU SEQRES 14 A 365 LYS ILE LEU ASP PHE GLY LEU ALA ARG HIS THR ASP ASP SEQRES 15 A 365 GLU MET THR GLY TYR VAL ALA THR ARG TRP TYR ARG ALA SEQRES 16 A 365 PRO GLU ILE MET LEU ASN TRP MET HIS TYR ASN GLN THR SEQRES 17 A 365 VAL ASP ILE TRP SER VAL GLY CYS ILE MET ALA GLU LEU SEQRES 18 A 365 LEU THR GLY ARG THR LEU PHE PRO GLY THR ASP HIS ILE SEQRES 19 A 365 ASP GLN LEU LYS LEU ILE LEU ARG LEU VAL GLY THR PRO SEQRES 20 A 365 GLY ALA GLU LEU LEU LYS LYS ILE SER SER GLU SER ALA SEQRES 21 A 365 ARG ASN TYR ILE GLN SER LEU THR GLN MET PRO LYS MET SEQRES 22 A 365 ASN PHE ALA ASN VAL PHE ILE GLY ALA ASN PRO LEU ALA SEQRES 23 A 365 VAL ASP LEU LEU GLU LYS MET LEU VAL LEU ASP SER ASP SEQRES 24 A 365 LYS ARG ILE THR ALA ALA GLN ALA LEU ALA HIS ALA TYR SEQRES 25 A 365 PHE ALA GLN TYR HIS ASP PRO ASP ASP GLU PRO VAL ALA SEQRES 26 A 365 ASP PRO TYR ASP GLN SER PHE GLU SER ARG ASP LEU LEU SEQRES 27 A 365 ILE ASP GLU TRP LYS SER LEU THR TYR ASP GLU VAL ILE SEQRES 28 A 365 SER PHE VAL PRO PRO PRO LEU ASP GLN GLU GLU MET GLU SEQRES 29 A 365 SER MODRES 4AA5 CSS A 162 CYS S-MERCAPTOCYSTEINE HET CSS A 162 7 HET NQB A1353 31 HETNAM CSS S-MERCAPTOCYSTEINE HETNAM NQB N-CYCLOPROPYL-4-METHYL-3-[6-(4-METHYLPIPERAZIN-1-YL)-4- HETNAM 2 NQB OXIDANYLIDENE-QUINAZOLIN-3-YL]BENZAMIDE FORMUL 1 CSS C3 H7 N O2 S2 FORMUL 2 NQB C24 H27 N5 O2 FORMUL 3 HOH *21(H2 O) HELIX 1 1 SER A 61 MET A 78 1 18 HELIX 2 2 SER A 95 PHE A 99 5 5 HELIX 3 3 LEU A 113 VAL A 117 1 5 HELIX 4 4 THR A 123 ALA A 144 1 22 HELIX 5 5 LYS A 152 SER A 154 5 3 HELIX 6 6 THR A 185 ARG A 189 5 5 HELIX 7 7 ALA A 190 LEU A 195 1 6 HELIX 8 8 THR A 203 GLY A 219 1 17 HELIX 9 9 ASP A 227 GLY A 240 1 14 HELIX 10 10 GLY A 243 LYS A 248 1 6 HELIX 11 11 SER A 252 LEU A 262 1 11 HELIX 12 12 ASN A 269 PHE A 274 1 6 HELIX 13 13 ASN A 278 LEU A 289 1 12 HELIX 14 14 ASP A 292 ARG A 296 5 5 HELIX 15 15 THR A 298 ALA A 304 1 7 HELIX 16 16 HIS A 305 ALA A 309 5 5 HELIX 17 17 ASP A 313 GLU A 317 5 5 HELIX 18 18 GLN A 325 ARG A 330 5 6 HELIX 19 19 LEU A 333 SER A 347 1 15 SHEET 1 AA 2 PHE A 8 LEU A 13 0 SHEET 2 AA 2 THR A 16 PRO A 21 -1 O THR A 16 N LEU A 13 SHEET 1 AB 5 TYR A 24 GLY A 33 0 SHEET 2 AB 5 GLY A 36 ASP A 43 -1 O GLY A 36 N GLY A 33 SHEET 3 AB 5 LEU A 48 LEU A 55 -1 O LEU A 48 N ASP A 43 SHEET 4 AB 5 TYR A 103 HIS A 107 -1 O LEU A 104 N LYS A 53 SHEET 5 AB 5 ASP A 88 PHE A 90 -1 O ASP A 88 N VAL A 105 SHEET 1 AC 3 ALA A 111 ASP A 112 0 SHEET 2 AC 3 LEU A 156 VAL A 158 -1 O VAL A 158 N ALA A 111 SHEET 3 AC 3 LEU A 164 ILE A 166 -1 O LYS A 165 N ALA A 157 LINK N CSS A 162 C ASP A 161 1555 1555 1.34 LINK C CSS A 162 N GLU A 163 1555 1555 1.34 SITE 1 AC1 13 VAL A 30 SER A 32 VAL A 38 ALA A 51 SITE 2 AC1 13 LYS A 53 GLU A 71 LEU A 75 ILE A 84 SITE 3 AC1 13 THR A 106 LEU A 167 ASP A 168 PHE A 169 SITE 4 AC1 13 HOH A2002 CRYST1 64.480 74.654 76.399 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015509 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013395 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013089 0.00000